Evidence map›Paper›PMID 35203386›Full record

ArticleCells2022

Aryl Hydrocarbon Receptor Activation by Benzo[

Christiane Fueldner, Sina Riemschneider, Janine Haupt, Harald Jungnickel, Felix Schulze, Katharina Zoldan, Charlotte Esser, Sunna Hauschildt, Jens Knauer, Andreas Luch and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. The role of the AHR in host-pathogen interactions.Nature reviews. Immunology · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Christiane FueldnerDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Sina RiemschneiderDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Janine HauptDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Harald JungnickelDepartment of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), 10589 Berlin, Germany.
Felix SchulzeDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Katharina ZoldanDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Charlotte EsserLeibniz Research Institute for Environmental Medicine, 40225 Düsseldorf, Germany.
Sunna HauschildtFaculty of Life Sciences, University of Leipzig, 04103 Leipzig, Germany.
Jens KnauerDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Andreas LuchDepartment of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), 10589 Berlin, Germany.
Stefan KalkhofDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Jörg LehmannDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.ORCID 0000-0001-8560-648X
Fraunhofer Institute for Cell Therapy and Immunology · DEFederal Institute for Risk Assessment · DEFraunhofer Research Institution for Materials Recycling and Resource Strategies IWKS · DECoburg University of Applied Sciences · DELeibniz Institute of Environmental Medicine · DELeipzig University · DE

Funding

Federal Institute for Risk Assessment FK 3-1329-432Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Internal project funding and CIMD_CED-AhR
6 · The paper itself

Abstract

This study focused on immunomodulatory effects of aryl hydrocarbon receptor (AhR) activation through benzo[

Indexed as

Basic Helix-Loop-Helix ProteinsReceptors, Aryl HydrocarbonSepsisShock, SepticAnimalsBenzo(a)pyreneDisease Models, AnimalMiceSalmonella entericaSalmonella Infections, AnimalAhr protein, mouseBasic Helix-Loop-Helix ProteinsBenzo(a)pyreneReceptors, Aryl Hydrocarbonaryl hydrocarbon receptor (AhR)benzo[a]pyrene (BaP)IL-10IL-22immunomodulationinterferon-γinterleukin (IL)-12Salmonella infectionseptic shocksystemic inflammatory response syndrome (SIRS)

Identifiers

PMID35203386
PMCPMC8870598
OpenAlexW4213331915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.